Scope of the journalJournal of Gene Therapy Aspects encompasses all the biological, clinical trials and medical aspects of potential gene therapies and treatment of genetic disorders through modification of gene expression. The scope of the journal also covers a wide spectrum of diseases, human gene therapy research, promise to unite View More...
Original ResearchOpen Access
View All articles ..
Gene therapy using synthetic microRNA directed against GAD67 has beneficial effect on motor behaviour in 6-OHDA lesioned ratsErika Elgstrand Wettergren, Luis Quintino, Cecilia Lundberg
Journal of Gene Therapy Aspects 1: 1
View All articles ..
Dr. Dario Marchetti presently working as Professor, Departments of Pathology and Molecular and Cellular Biology, Baylor College of Medicine. His main research areas include Cancer invasion and metastasis, Brain metastasis, Angiogenic mechanisms in cancer and other pathologies.
Dr. Raj Kumar presently working as Professor in Biochemistry Department at The Commonwealth Medical College (TCMC), USA. His main research areas include Protein structure and functions, Macromolecular interactions, Cell signaling and Gene Regulation, Cancer, Endocrinology, Steroid hormone receptors, Post translational Modifications, Neurodegenerative diseases, Structure-based drug discovery.
Dr. James CS Chim presently working as Professor in Haematology & Oncology, Department of Medicine, University of Hong Kong and Honorary Consultant, Queen Mary Hospital. He is a clinician scientist interested in clinical and translational studies in multiple myeloma, lymphoma and leukemia.
Journal of Gene Therapy Aspects Subject Areas
Gene Therapy for Genetic Disorders, Gene Therapy for Acquired Diseases, Somatic gene therapy, Germ line gene therapy, Vectors in gene therapy, Developments in gene therapy, Preventive gene therapy, Pharmacological gene therapy, Predictive medicine, Therapeutic gene modulation, Whole genome sequencing, Clinical trials- Gene therapy, Molecular genetics, Virology- Gene therapy, Inherited disorders, Oligonucleotide- and cell-based therapeutics, Pre-clinical target validation.